Page last updated: 2024-08-16

corticosterone and jnj-31020028

corticosterone has been researched along with jnj-31020028 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aluisio, L; Atack, JR; Bonaventure, P; Carruthers, NI; Dvorak, C; Dvorak, L; Fraser, I; Galici, R; Lord, B; Lovenberg, TW; Morton, K; Motley, ST; Nepomuceno, D; Shoblock, JR; Sutton, SW; Swanson, DM; Welty, N	1
Aydin, C; Isgor, C; Oztan, O	1

Other Studies

2 other study(ies) available for corticosterone and jnj-31020028

Article	Year
In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptor. Psychopharmacology, 2010, Volume: 208, Issue:2 Topics: Administration, Oral; Animals; Anorexia; Anti-Anxiety Agents; Anxiety; Autoradiography; Benzamides; Binding, Competitive; Calcium; CHO Cells; Corticosterone; Cricetinae; Cricetulus; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Feeding Behavior; Hippocampus; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Mice; Microdialysis; Norepinephrine; Peptide YY; Permeability; Piperazines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Neuropeptide Y; Transfection; Vas Deferens	2010
Effects of a selective Y2R antagonist, JNJ-31020028, on nicotine abstinence-related social anxiety-like behavior, neuropeptide Y and corticotropin releasing factor mRNA levels in the novelty-seeking phenotype. Behavioural brain research, 2011, Sep-23, Volume: 222, Issue:2 Topics: Amygdala; Animals; Anxiety; Benzamides; CA3 Region, Hippocampal; Corticosterone; Corticotropin-Releasing Hormone; Disease Models, Animal; Exploratory Behavior; Interpersonal Relations; Male; Motor Activity; Neuropeptide Y; Nicotine; Phenotype; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Neuropeptide Y; RNA, Messenger; Substance Withdrawal Syndrome	2011

Article

Year

In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptor.

Psychopharmacology, 2010, Volume: 208, Issue:2

Topics: Administration, Oral; Animals; Anorexia; Anti-Anxiety Agents; Anxiety; Autoradiography; Benzamides; Binding, Competitive; Calcium; CHO Cells; Corticosterone; Cricetinae; Cricetulus; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Feeding Behavior; Hippocampus; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Mice; Microdialysis; Norepinephrine; Peptide YY; Permeability; Piperazines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Neuropeptide Y; Transfection; Vas Deferens

2010

Effects of a selective Y2R antagonist, JNJ-31020028, on nicotine abstinence-related social anxiety-like behavior, neuropeptide Y and corticotropin releasing factor mRNA levels in the novelty-seeking phenotype.

Behavioural brain research, 2011, Sep-23, Volume: 222, Issue:2

Topics: Amygdala; Animals; Anxiety; Benzamides; CA3 Region, Hippocampal; Corticosterone; Corticotropin-Releasing Hormone; Disease Models, Animal; Exploratory Behavior; Interpersonal Relations; Male; Motor Activity; Neuropeptide Y; Nicotine; Phenotype; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Neuropeptide Y; RNA, Messenger; Substance Withdrawal Syndrome

2011